Observational studyThe Journal of international medical research2020
Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease.
Observational study in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Dual Antiplatelet Therapy in Acute Branch Atheromatous Disease (BAD)-Related Stroke: A Multicenter Propensity-Matched Cohort Analysis.CNS neuroscience & therapeutics · 2026Article
- Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual-Method Analysis Using Propensity Score Matching and Multivariable Regression.CNS neuroscience & therapeutics · 2025Article
- Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity-Matched Analysis From MRI-Based Study.CNS neuroscience & therapeutics · 2025Article
- Safety and efficacy of tirofiban after intravenous thrombolysis with urokinase in patients with acute ischemic stroke.Frontiers in neurology · 2025Article
- Article
- Pathophysiology and Optimal Treatment of Intracranial Branch Atheromatous Disease.Journal of atherosclerosis and thrombosis · 2023Review
- Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study.BMC neurology · 2022Article
- Risk factors for early neurological deterioration in acute isolated pontine infarction without any causative artery stenosis.BMC neurology · 2022Article
- Human urinary kallidinogenase may improve the prognosis of acute stroke patients with early neurological deterioration.Brain and behavior · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effects of early administration of tirofiban after intravenous thrombolysis on early neurological deterioration in patients with branch atheromatous disease.
methodsWe analyzed clinical data from patients with branch atheromatous disease. We enrolled seven cases into the urokinase-only (UO) control group and 10 cases into the urokinase + tirofiban (UT) treatment group. National Institutes of Health Stroke Scale (NIHSS) scores were obtained at admission and on days 3 and 5 after admission. Modified Rankin Scale (mRS) scores were obtained 3 months after admission.
resultsSignificant differences between the UO and UT groups were evident on days 3 and 5 after admission. In the UT group, there was a significant difference between NIHSS scores at admission and on day 5, while there were no significant differences in scores in the UO group. The early neurological deterioration rates were not significantly different between the two groups. However, there were significant differences in these rates at 72 and 120 hours. Both the mRS scores and the prognoses at 3 months differed between the two groups.
conclusionEarly administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration and improves the long-term prognosis of patients with branch atheromatous disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.